글로벌 클렙시엘라 감염 시장 – 2029년까지의 산업 동향 및 예측

클렙시엘라 감염 시장 분석 및 규모

글로벌 클렙시엘라 감염 시장은 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. 전 세계적으로 클렙시엘라 감염의 유병률이 증가하고 신흥 시장이 이 시장 성장을 책임지는 요인입니다. 이 시장은 치료 절차의 증가, 정부에서 지원하는 R&D 활동, 이 지역의 인구 증가로 인해 상승하고 있습니다. 클렙시엘라는 모든 병원 감염의 약 8%를 차지합니다. COVID-19도 시장 성장에 큰 영향을 미쳤습니다.

 Data Bridge Market Research는 2022-2029년 예측 기간 동안 글로벌 클렙시엘라 감염 시장의 성장률을 분석합니다. 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크도 포함됩니다.

시장 정의

클렙시엘라 감염은 대부분 병원에서 발생하며 면역 체계가 약한 환자는 이러한 감염에 더 취약합니다. 면역 체계가 약한 환자나 의료 기기를 이식한 환자는 클렙시엘라 감염 위험이 더 높습니다. 항생제의 광범위한 사용으로 인해 항생제 내성 클렙시엘라 균주가 개발되었습니다.

보고 범위 및 시장 세분화

Global Klebsiella Infection Market Dynamics

Drivers

• Increased Demands of Diagnostic Tests

Different kinds of diagnostic procedures are helping to create opportunities of the global Klebsiella infection market. Tests such as laboratory tests, ultrasound, X-rays and many such other tests are available today with regards to this. All these factors are also contributing in the growth of the market

• Increase in the number of research and development activities       

The market's growth is fueled by increase in the number of R&D activities. This will provide beneficial advantages for the global Klebsiella infection market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives. For instance, Tetraphase Pharmaceuticals, Inc. was funded with USD 67 million for the development of its pipeline drug TP-434. This is a potent antibiotic effective against multi drug resistant (MDR) gram negative microorganism and can aid in providing effective treatment in Klebsiella infection.

Opportunities

• Availability of Advanced Treatment Procedures

With each passing decade, varied treatment methods are being available that would help the patients' faster recovery. Treatment advancements in terms of new antibiotics are on the rise. Thus, it creates many opportunities in the market growth.

• Increasing Demand for Retail Pharmacies

The rise in the number of perinatal infections therapeutics being delivered through the retail pharmacies and the rising number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global Klebsiella infection market over a forecast period.

• High Cost

The huge expenditure associated with Klebsiella infections medications surely hamper the market growth.

This global Klebsiella infection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Klebsiella infection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Klebsiella infection Market Scope

The global Klebsiella infection market is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Moxifloxacin
• Ofloxacin
• Levofloxacin
• Ceftriaxone

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Klebsiella Infection Market Regional Analysis/Insights

The global Klebsiella infection market is analysed and market size insights and trends are provided by treatmnet, distribution channel and end-user as referenced above.

The major countries covered in the global Klebsiella infection market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global Klebsiella infection market throughout the forecasted period due to rising prevalence of the infection

Asia-Pacific dominates the market due to increased WHO & government awareness programs.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Klebsiella Infection Market Share Analysis

글로벌 클렙시엘라 감염 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 제공된 위의 데이터 포인트는 글로벌 클렙시엘라 감염 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 클렙시엘라 감염 시장에서 활동하는 주요 기업은 다음과 같습니다.

• Procarta Biosystems(영국)
• 라호야제약(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Pfizer Inc. (미국), Novartis AG (스위스)
• 아스트라제네카(영국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• Sun Pharmaceutical Industries Ltd. (인도)
• 브리스톨-마이어스 스퀴브 회사(미국)
• 릴리(미국)
• 암젠 주식회사(미국)
• 머크 KGaA(독일)
• Beckman Coulter Inc. (미국)
• bioMerieux (프랑스)
• Bio-Rad Laboratories, Inc (미국)
• 퀴델 코퍼레이션(미국)
• Eiken Chemical Co., Ltd.(일본)
• 멜린타 테라퓨틱스 LLC(미국)
• Northern Antibiotics Ltd(핀란드)
• 스미토모파마 주식회사(일본)

SKU-69222